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Abstract
Background: Tuberculosis is a growing international health concern. It is the biggest killer among
the infectious diseases in the world today. Early detection of drug resistance allows starting of an
appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes
of Mycobacterium tuberculosis(MTB). The aim of this study was to identify the presence of
Isoniazid (INH) and Rifampicin(RIF) drug resistance in new and previously treated tuberculosis (TB)
cases using DNA sequencing.
Methods: This study was carried out on 153 tuberculous patients with positive Bactec 460 culture
for acid fast bacilli.
Results: Of the 153 patients, 105 (68.6%) were new cases and 48 (31.4%) were previously treated
cases. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first
line antituberculous. Genotypic analysis was done only for rifampicin resistant specimens (23 cases)
and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR
amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases.
Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes.
Genotypic analysis of RIF resistant cases revealed that 20/23 cases (86.9%) of RIF resistance were
having rpoB gene mutation versus 3 cases (13.1%) having no mutation with a high statistical
significant difference between them (P < 0.001). Direct sequencing of Kat G gene revealed point
mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG i.e. no evidence of
mutation with a high statistical significant difference between them (P < 0.001).
Conclusion: We can conclude that rifampicin resistance could be used as a useful surrogate
marker for estimation of multidrug resistance. In addition, Genotypic method was superior to that
of the traditional phenotypic method which is time-consuming taking several weeks or longer.
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Background
Tuberculosis is a growing international health concern. It
is the biggest killer among the infectious diseases in the
world today, despite the use of a live attenuated vaccine
and several antibiotics. After years of decline, TB has re-
emerged as a serious public health problem worldwide,
especially with increased drug resistance among MTB
strains which hinders the success of TB control pro-
grams[1]. Isolation, identification, and drug susceptibility
testing of MTB and other clinically important mycobacte-
ria can take several weeks because of its slow growth rate.
During the past several years, many molecular methods
have been developed which can potentially reduce the
diagnostic time from weeks to hours. Early detection of
drug resistance allows starting of appropriate treatment,
which has an impact on better control of the disease[2].
Resistance to drugs is due to particular genomic mutations
in specific genes of MTB. To date, nine genes are known to
be linked to resistance to first-line anti-TB drugs; katG,
inhA, aphC, and kasA for INH resistance, rpoB for RIF
resistance, rpsL and rrs for strptomycin (STR) resistance,
embB for ethambtol (EMB) resistance, and pncA for
pyazinamid (PZA) resistance. Resistance to multiple drugs
is the consequence of an accumulation of mutations[3].
RIF interferes with transcription and elongation of RNA
by binding to the β-subunit of RNA polymerase. The rpoB
gene encodes RNA polymerase enzyme of MTB. So, any
mutation in 81 bp hypervariable region of the rpoB gene
results in failure of binding and subsequently resist-
ance[4]. The katG gene encodes mycobacterial catalase
peroxidase which is the only enzyme in MTB capable of
activating the pro-drug INH to active form. Furthermore,
katG gene is involved in detoxification of endogenously
generated or exogenously supplied hydrogen peroxide[5].
Aim of the work
This study was designed to identify the presence of INH
and RIF drug resistance in new and previously treated
tuberculosis (TB) cases using DNA sequencing.
Methods
Patients
This study was carried out on 153 tuberculous patients
(83 males and 70 females) with positive Bactec 460 cul-
ture for acid fast bacilli. They were selected from Man-
soura University Hospitals and Mansoura chest hospital.
Drug susceptibility testing on Bactec revealed 50 resistant
cases for one or more of the first line antituberculous (Iso-
niazid, rifampicin, ethambutol and streptomycin). All
resistant TB cases were subjected to full history taking
especially for past history of similar conditions, intake of
antituberculous drugs, clinical and radiological examina-
tions. They were 33 males and 17 females with their ages
ranging from 19 to 52 years. Informed written consents
were taken from all patients and the study was approved
by the Ethics Committee of Mansoura University.
Definitions
Patients were classified into two groups according to their
treatment history at the time of diagnosis: new cases,
which included patients who had never received anti-TB
treatment or who had received treatment for <4 weeks,
and previously treated cases, which included patients who
had taken anti-TB drugs for at least 4 weeks [6]. Initial
resistance was defined as the presence of drug-resistant M.
tuberculosis strains in new cases. Acquired resistance was
defined as the presence of drug-resistant M. tuberculosis
strains in patients who were reported to have received
anti-TB treatment for >4 weeks. Mono resistance was
defined as resistance to only one of the four first-line 8
drugs. Multidrug resistance (MDR) was defined as resist-
ance to at least Isoniazid and rifampicine [7,8].
Collection of the specimens
Three consecutive spontaneously produced early morning
sputum samples were collected from patients with pulmo-
nary TB. Samples were collected in sterile containers to
avoid contamination with environmental bacteria e.g.
Mycobacterium xenopi.
Laboratory methods
All resistant TB cases were subjected to detection of tuber-
cle bacilli and anti-tuberculous drug susceptibility testing
by radiometric method (BACTEC 460 system, Becton
Dickinson microbiology Systems, Cockeysville, M.A.
21030, 800-638-8663).
Genotypic analysis was done only for rifampicin resistant
specimens (23 cases) and INH resistant specimens (26
cases) to detect mutations responsible for drug resistance
by PCR amplification of rpoB gene for rifampicin resistant
cases and KatG gene for isoniazid resistant cases. Finally,
DNA sequencing was done for detection of mutation
within rpoB and KatG genes.
Molecular characterization of resistant strains
It included three main steps:
1-DNA extraction to release DNA from mycobacterial
cells.
Table 1: Amplification master mix
Component Volume/sample
Sterile nuclease free water 3 ul
Forward primer 6 ul
Reverse Primer 6 ul
Master mix 25 ul
DNA template 10 ul
Final volume 50 ulAnnals of Clinical Microbiology and Antimicrobials 2009, 8:4 http://www.ann-clinmicrob.com/content/8/1/4
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2-Amplification of the target part of gene by PCR and
detection by agarose gel electrophoresis.
3-Automated DNA sequencing to detect mutation in com-
parison with the similar region of a wild strain[9].
1-DNA extraction
QIAamp DNA Mini kit was used to purify total DNA from
decontaminated sputum samples (Qiagen Inc. 28159
Avenue Stanford, Valencia, CA 91355. fax 800-718-2056,
USA).
2-DNA amplification
PCR amplification of rpoB & KatG genes
A 157-bp fragment of the rpoB gene, from nucleotide
1846 to 2002 (Gen Bank accession no. U12205) was
amplified by using the primers TR9(TCGCCGCGAT-
CAAGGAGT)and TR8(TGCACGTCGCGGACCTCCA).
The 200-bp KatG fragment targetting codon 315 from
nucleotide 904 to 1103 (Gen Bank accession no. X68081)
was amplified by using primers KatGIF(AGCTCGTAT-
GGCACCGGAAC) and KatG4RB(AACGGGTCCGGGAT-
GGTG).
Qiagen taq PCR Master (250 Unit): (2× concentrated,
contains polymerase, PCR buffer with 3 mM MgCl2 and
400 mM of each dNTP).
Procedure
Master mix was prepared as shown in Table 1. The
required volume for each sample was multiplied by the
number of samples and adding a negative control plus
one. The mixture was mixed by vortex and dispensed (50
ul) in each tube. PCR tubes were placed in the thermal
cycler under the appropriate amplification conditions
(Table 2). Each PCR was preceded by a single denatura-
tion step at 94°C for 4 min. and terminated with a single
primer extension step at 72°C for 8 min. The last cycle was
followed by cooling to 4°C and holding at this tempera-
ture until the tubes were taken out off the machine.
3-DNA Sequencing
This was done by the use of ABI Prism 310 Genetic Ana-
lyzer (figure 1), (Applied Biosystems, Foster city, Calif.,
944041 USA).
Statistical analysis
Data entry and analysis were performed using SPSS statis-
tical package for social science version 10 (SPSS, Inc., Chi-
cago, IL, USA). The quantitative data were presented as a
mean and standard deviation and the qualitative data
were presented as number and percentage. The chi-square
(χ2) was used to find the association between row and
column variables of qualitative data. The threshold of sig-
nificance is fixed at 5% level (P value). P value of > 0.05
indicates non-significant results; P value of < 0.05 indi-
cates a significant result while, P value of < 0.001 indicates
a high significant result.
Discussion
Tuberculosis, one of the oldest recorded human diseases,
is still one of the biggest killers among the infectious dis-
eases, despite the use of a live attenuated vaccine and sev-
eral antibiotics. The development of drug resistance in the
population has increased the possibility that TB may once
again become an incurable disease[10]. Resistance to
drugs is due to particular genomic mutations in specific
genes of MTB. To date, nine genes are known to be linked
to resistance to first-line anti-TB drugs; katG, inhA, aphC,
and kasA for INH resistance, rpoB for RIF resistance, rpsL
Table 3: Characteristics of the study population (n = 153)
Mean age, years (range) 38 (19–52)
Male patients 83 (54.3%)
Female patients 70 (45.7%)
Urban 58 (38%)
Rural 97 (62 %)
Previous TB treatment 48 (31.4%)
New cases 105 (68.6%)
Susceptible TB cases 103(67.3%)
Resistant TB cases 50(32.7%)
Table 2: Amplification conditions.
Gene Denaturation Annealing Extension No. of cycles
rpoB 94°C, 1 min. 55°C,1 min. 72°C, 1 min. 40 cycles
Ka G 94°C, 1 min. 61°C, 1 min. 72°C, 1 min. 30 cycles
Sequencing reaction obtained from labeled amplified genes by  ABI 310 Sequencer Analyzer Figure 1
Sequencing reaction obtained from labeled amplified 
genes by ABI 310 Sequencer Analyzer.Annals of Clinical Microbiology and Antimicrobials 2009, 8:4 http://www.ann-clinmicrob.com/content/8/1/4
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and rrs for STR resistance, embB for EMB resistance, and
pncA for PZA resistance. Resistance to multiple drugs is the
consequence of an accumulation of mutations[3].
Because the organism is slow growing, traditional deter-
mination of resistance is time-consuming as it may take
several weeks or longer. Rapid detection of drug resistance
could optimize treatment, improve outcome for patients
with drug-resistant tuberculosis and prevent transmission
of drug-resistant TB. Genotypic methods have the advan-
tage of a shorter turnaround time, no need for growth of
the organism, possibility for direct application in clinical
samples, less biohazard risks, and feasibility for automa-
tion [8].
Therefore, the aim of this study was to identify the pres-
ence of INH and RIF drug resistance in new and previously
treated tuberculosis (TB) cases using DNA sequencing. To
achieve this aim, 153 tuberculous patients with cultures
positive for acid fast bacilli were selected from Mansoura
University and Chest Hospitals (Table 3). Out of 153
tuberculous patients, 50 resistant cases to one or more of
the first line antituberculous drugs (isoniazid, rifampi-
cine, ethambutol and streptomycin) were selected after
drug susceptibility testing by BACTEC 460. All of them
were identified by NAP test as Mycobacterium tuberculo-
sis complex. They were 33 males and 17 females with their
ages ranging from 19 to 52 years. From 50 resistant cases,
genotypic analysis was done only for 23 rifampicine
resistant cases (rpoB gene) and 26 isoniazid resistant cases
(KatG gene) to detect mutation responsible for drug resist-
ance by automated DNA sequencer (ABI Prism 310
Genetic Analyzer).
The rate of drug resistance (table 4) was 32.7% (50/153
cases), with a higher prevalence of resistance in patients
who had received previous anti-tuberculous treatment
(70 %) than new patients (30%). This was in accordance
with those reported in Saudi Arabia by Al-Hajjaj et al [11]
that was 29.7% of 101 MTB isolates. However, a higher
prevalence of resistance was found in Russia by Toung-
oussova et al.[12] that was 56.3% among 119 MTB iso-
lates. Also, in Greece, Tarkada et al.[13] found 51.2% of
207 initial isolates of MTB. While a lower prevalence of
resistance was reported by Rivera et al.[14] who studied
188 MTB in Philippines and noted that drug-resistance
represented 17.6% of isolates. And in Qatar, by Al-Marri
[15] who found 61(15%) among 406 MTB isolates. This
low prevalence of resistance to four anti-tuberculous
drugs may be due to screening programs (chest radiogra-
phy) and implementation of directly observed therapy,
short course(DOTS).
Regarding prevalence of primary and secondary resist-
ance, there was a higher prevalence of resistance in
patients who received previous antituberculous treatment
(70%) than patients with no previous treatment (30%).
These results are fully consistent with other reports
[4,16,17] stating that resistance was significantly higher in
previously treated cases (71%, 63%, and 95%; respec-
tively) than in new cases.
Antituberculous drug susceptibility testing by BACTEC
system in the present study (table 5) revealed that INH
had the highest resistance (52%), followed by Rifampi-
cine (46%), Ethambutol (44%) and the lowest resistance
was encountered with Streptomycin (36%). Also,
Dawood [18] found that the drug resistance in TB cases
were; 73 %, 63 %, 27 % and zero % to INH, Streptomycin,
RIF and ETH; respectively. On the other hand, Annelies et
al.[3] reported that resistance was 93%, 56%, 41% and
18% to INH, RIF, STR and EMB; respectively. The signifi-
cant increase in rifampicin, INH and ethambutol resist-
ance in the last 10 years could be attributed to poor
compliance and wide use of these drugs for non-tubercu-
losis conditions. While, the high sensitivity of streptomy-
cin was attributed to the restriction of its use in the
management of tuberculous patients[18]. Furthermore, it
could be noticed that the association of RIF resistance
with other drugs (table 6, 7) was significantly higher 17/
Table 5: Drug susceptibility testing of resistant TB cases by 
BACTEC (50 cases)
Antituberculous drug Sensitive Resistant
No % No %
Streptomycin 32/50 64% 18/50 36%
INH 24/50 48% 26/50 52%
Rifampicine 27/50 54% 23/50 46%
Ethambutol 28/50 56% 22/50 44%
Table 4: Previous anti-TB treatment in 50 resistant TB cases
Resistant TB cases (50)
No %
Previous anti-TB treatment(Secondary resistance) 35 70
No previous treatment (Primary resistance) 15 30Annals of Clinical Microbiology and Antimicrobials 2009, 8:4 http://www.ann-clinmicrob.com/content/8/1/4
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50 (34%) than RIF resistance alone 6/50 (12%). On the
other hand, the association of INH resistance with other
drugs 16/50 (32%) and INH resistance alone 10/50 cases
(20%) was insignificant (P > 0.05). Similar results were
found in 1999 by Narar et al.[19] who noted statistical sig-
nificant difference between resistance to RIF only (5%)
and resistant to RIF in association with other drugs
(32.5%). So, Albert et al. [20] stated that rifampicine
resistance has been identified as a useful surrogate marker
for estimation of multidrug resistance and indicated that
the second line drugs are urgently required.
Genotypic analysis of RIF resistant cases (table 8) revealed
that 20/23 cases (86.9%) showed rpoB gene mutation ver-
sus 3 cases (13.1%) having no mutation. A discrepancy
between the results of the phenotypic and genotypic drug
resistance tests (absence of mutation in 13.1% of pheno-
typically resistant isolate) could be attributed to the pres-
ence of other mutations located either outside the selected
target regions (codon position) or outside the selected
gene itself (rpoB gene). Another explanation was the so
called "heteroresistance" that means the presence of mix-
ture of susceptible and resistant subpopulation in culture
which could be an obstacle against the sensitivity of
molecular drug resistance testing and the successive ther-
apy[21].
The commonest point mutation (table 9 & figure 2) was
found at codon 531 in 9/20 (45%) with serine-->leucine
substitution (TCG-->TTG). The second type of mutation
was detected at codon 526 in 6/20 (30%) with histidine -
->aspartate substitution (CAC-->GAC), followed by
codon 516 in 4/20 (20%) with aspartate--> valine substi-
tution (GAC-->GTC). The lowest point mutation was
found at codon 522 in 1/20 (5%) with serine--> leucine
substitution (TCG-->TTG). These results were similar to
Kim et al.[22] in Korea, who found high-mutation fre-
quencies of codon 526 (37.8%) and codon 531 (24.4%)
in rifampin-resistant strains. Also, these findings were
more or less in agreement with those results of the United
States[23,24], Japan[25,26], Australia[27], Asia [28]Brazil
and France,[29] China,[30] and in Netherlands[31].
In other similar studies in accordance to our data; Khamis
et al.[32] found ten out of the eleven rifampicin resistant
specimens (90.9%) showing gene mutation versus only
one (9.1%) with no mutation. Point mutations was at
codon 516 in 4/10 (40%) with aspargine → valine substi-
tution (CAG → CTG). The second type of mutation was
detected at codon 526 in 2/10 (20%) with histidine (H)
→ tyrosine (Y) substitution (CAC→GAC) and the last
mutation was at codone 531 in 4/10 (40%) with serine
(S) →leucine (L) substitution (TCG →TTG). Isfahani et al
[4] in Iran analyzed 21 RIF resistant isolates and found
point mutation in the 81-bp region of the rpoB gene in 18
strains (85.7%) and 3 strains (14.3%) had no mutations.
The commonest point mutation was found at codon 531
in 10 cases (47.5%) with serine-->leucine substitution,
followed by codon 526 in 4 cases (19.1%) with histidine
--> aspargine substitution and codon 516 in one case
(4.75%) with aspargine --> valine substitution.
Table 7: Different association of drug resistance in studied 
resistant cases.
Type of resistance Resistant cases(50)
No %
One drug resistance 24 46
RIF 61 2
INH 10 20
SM 48
EMB 48
Two drug resistance 16 32
RIF+INH 51 0
RIF+EMB 24
INH+SM 12
INH+EMB 24
SM+EMB 61 2
Three drug resistance 7 14
RIF+INH+SM 24
RIF+INH+EMB 36
RIF+ SM+EMB 24
Four drug resistance
RIF+INH+EMB+SM 36
Table 6: Phenotypic resistance pattern among RIF&INH resistant cases
Phenotypic resistance pattern No % X2 P
RIF resistance alone (Monoresistance) 6/50 12%
RIF resistance with other drugs (Multidrug resistance) 17/50 34% 0.526 0.022*
INH resistance alone (Monoresistance) 10/50 20% 1.38 0.239
INH resistance with other drugs(Multidrug resistance) 16/50 32%
￿ P value of < 0.05 is significant.Annals of Clinical Microbiology and Antimicrobials 2009, 8:4 http://www.ann-clinmicrob.com/content/8/1/4
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On the other hand, in contrast to the above mentioned
studies, Heep et al.[21] had shown a total mutations of
100% at completely unique codon positions apart from
codon position mentioned in our study and other studies
at codons 176, 441, 451 and 456. This indicates continu-
ous emergence of new codon mutations every now and
then.
Direct sequencing of KatG gene revealed point mutation
in 24/26 (92.3%) and the remaining 2/26 (7.7%) had
wild type KatG (no evidence of mutation) with high sta-
tistical significant difference between them (P < 0.001).
Point mutation was found only at codon 315 (figure 3) in
24/24 (100%) with serine --->threonine substitution
(AGC-->ACC). Our results had supported the hypothesis
of linking katG gene mutation to the development of INH
resistance in MTB. The katG gene encodes mycobacterial
catalase peroxidase which is the only enzyme in MTB
capable of activating the pro-drug INH to active form. Fur-
thermore,  katG  gene is involved in detoxification of
endogenously generated or exogenously supplied hydro-
gen peroxide[5]. The absence of mutation in 7.7% of
resistant isolates could be attributed to possible involve-
ment of other codon positions at the same gene or other
genes rather than the studied katG.
Our data are in concordance with those reported in the
Netherlands by Van Soolingen et al.[31], in Northwestern
Russia by Mokrousov et al.[33], in China by Huo and
Ge[34], in Lithuania by Bakonyte et al.[17], and in Ger-
many by Hillemann et al [2] who analyzed 103 multid-
rug-resistant and 40 fully susceptible strains where
mutation in katG codon 315 was detected in 91 of the 103
MDR strains (88.4%)with (AGC-->ACC) substitution and
none of the 40 susceptible strains had mutations.
On the contrary, in Finland, a low prevalence of muta-
tions in codon 315 was detected by Martilla et al.[35] who
examined 54 INH-resistant isolates and found 100% katG
point mutation with 7.5% only had codon 315 substitu-
tion and the remaining mutation positions were at other
codons rather than 315. In addition, Ahmad et al.[36,37]
found that mutation in codon 315 was detected in 18
(64%) out of 28 isoniazid-resistant isolates from Dubai
and in six (35%) out of 17 resistant strains from Beirut.
None of the susceptible strains contained this mutation.
The genotyping studies showed that the majority of the
isolates carrying AGC-->ACC substitution.
Conclusion
From the previous results, the currently available molecu-
lar methods are designed to determine the expected muta-
Identification and location of mutation of KatG gene detected  by DNA Sequencing in INH resistant cases Figure 3
Identification and location of mutation of KatG gene 
detected by DNA Sequencing in INH resistant cases.
Table 8: Frequency of mutations among RIF resistant cases (rpo B gene) & INH resistant cases (KatG gene)
Mutation No mutation Total X2 P
RIF resistant cases (rpo B) 20 (86.9%) 3 (13.1%) 23(100%) 12.56 <0.001
INH resistant cases (Kat G) 24 (92.3%) 2 (7.7%) 26(100%) 18.16 <0.001
rpoB gene mutations detected by DNA sequencing in RIF  resistant cases Figure 2
rpoB gene mutations detected by DNA sequencing in 
RIF resistant cases.Annals of Clinical Microbiology and Antimicrobials 2009, 8:4 http://www.ann-clinmicrob.com/content/8/1/4
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tions within specific codons of the rpoB and katG genes.
Therefore, although the molecular methods may aid in
the rapid detection of mutations associated with drug
resistance, there are major limitations to the molecular
genetic detection of drug resistance; it detects only muta-
tions that are screened for, while phenotypic tests detect
resistance independent of the underlying mechanism and
not all mutations conferring resistance to anti-TB drugs
are known. This fact is especially a problem in the detec-
tion of INH resistance because of multiple genes involved.
In addition, only few mutations conferring resistance to
second-line drugs are known[30].
In summary, rifampicin resistance could be used as a use-
ful surrogate marker for estimation of multidrug resist-
ance and the second line drugs are urgently required. In
addition, genotypic method was superior to that of the
traditional phenotypic method which is time-consuming
taking several weeks or longer. Moreover, the molecular
technique, automated DNA sequencing, inspite of its high
cost is of value in rapid detection of drug resistance (8
hours) resulting in improving the ability of clinicians to
optimize early therapy. It has the advantage of a shorter
turnaround time, no need for growth of the organism,
possibility for direct application in clinical samples, can
detect few numbers of bacilli, less biohazard risks and fea-
sibility for automation. However, Further studies are
needed using the automated DNA sequencing technique
to identify other codon mutations associated with resist-
ance to other anti-tuberculous drugs to obtain a standard-
ized drug resistance data in Egypt.
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